The European Patent Office has granted Evoke Pharma patent no. 2376075 for its EVK-001 intranasal metoclopramide for the treatment of diabetic gastroparesis symptoms in women, the company said. Earlier this year, Evoke announced that Phase 3 development of EVK-001 has been delayed by slower than expected enrollment in an ongoing clinical trial.
Evoke President and CEO Dave Gonyer commented, “While we continue our efforts to complete the Phase 3 clinical trial of EVK-001 and file a New Drug Application in the US, this European patent provides additional support and opportunities for the company as we work to offer a safe and effective treatment to gastroparesis patients globally. We are excited about the potential to bring this novel and patented intranasal product to market and help those suffering from this difficult disease.”
Read the Evoke Pharma press release.
